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Abstract
Background: Heimler syndrome (HS) is a rare hereditary systemic disorder, partial clinically overlapping with Usher
syndrome. So far, our knowledge of HS is very limited, many cases are misdiagnosed or may not even be
diagnosed at all. This study aimed to analyze the clinical and genetic characteristics of HS, and to evaluate potential
phenotype–genotype correlations.
Results: Two HS cases caused by PEX1 mutations were identified, and a novel likely pathogenic mutation, PEX1
c.895_896insTATA, was found. The main ophthalmic finding of the two patients was consistent with retinitis
pigmentosa accompanied by cystoid macular edema, but short axial length and hyperopia were also observed as
two previously unreported ocular phenotypes. Analysis of the literature showed that of the 29 HS patients
previously reported, 12 had PEX6 mutations, 10 had PEX1 mutations, two had PEX26 mutations, and the remaining
patients were not genetically tested. Three novel genotype–phenotype correlations were revealed from analysis of
these patients. First, most genotypes of every HS patient include at least one missense variant; second, at least one
mutation in PEX1 or PEX6 gene affects the AAA-ATPase region in every HS patient with retinal dystrophy,
suggesting AAA-ATPase region is a hypermutable region in patients with a retinal dystrophy; third, there are no
significant differences between PEX1-, PEX6-, and PEX26-associated phenotypes.
Conclusion: Next-generation sequencing is important for the diagnosis of HS. This study expands the clinical and
genetic spectrum of HS, and provides additional insights into genotype–phenotype correlations, which is vital for
accurate clinical practice, genetic counseling, and pathogenesis studies.
Keywords: Heimler syndrome, Next-generation sequencing, Genetic diagnosis, PEX1, PEX6, Genotype–phenotype
Background
Heimler syndrome (HS) was first reported in 1991 by A.
Heimler as an inherited syndrome characterized by sen-
sorineural hearing loss (SNHL), enamel hypoplasia, and
nail abnormalities [1]. Biallelic mutations in the peroxi-
somal biogenesis factor 1 gene (PEX1; MIM*602136), per-
oxisomal biogenesis factor 6 gene (PEX6; MIM*601498),
and peroxisomal biogenesis factor 26 gene (PEX26; MIM*
608666) are responsible for HS [2–4]. The proteins they
encode function together to control peroxisomal matrix
protein import, and mutations of these genes are
implicated in peroxisome biogenesis disorders (MIM
phenotypic series PS214100). These are characterized by a
deficiency of essential peroxisomal functions or even a
complete loss of functional peroxisomes, resulting in a
wide range of phenotypes that vary in severity [5, 6]. Pa-
tients with the most serious phenotype present at birth
only live a few weeks or months (Zellweger syndrome) [7],
while some disorders generally present later in childhood,
primarily with leukodystrophy, SNHL, retinal dystrophy,
and developmental and cognitive delay. Others may have
multiple organ dysfunction and psychomotor impairments
including craniofacial dysmorphism, neurological abnor-
malities, sensory defects, and liver, kidney, and bone ab-
normalities [5]. Therefore, patients with HS represent the
mildest phenotypic subgroup [8, 9].
Our current knowledge of HS is very limited, with
only 29 reported patients worldwide; 26 of these have
genetic sequence information [1–4, 9–14]. HS is also a
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systemic disease with a variety of other co-existing con-
genital abnormalities, and diagnostic criteria have not
been proposed [2, 15]. The HS clinical phenotype varies,
but includes acquired SNHL, amelogenesis imperfecta of
the teeth, and retinal dystrophy, partially clinically
overlapping with Usher syndrome that is character-
ized by congenital deafness, retinitis pigmentosa (RP),
presence or absence of vestibular dysfunction, but no
dental anomalies [4]. Although the number of re-
ported cases is small, this does not reflect a low inci-
dence of disease; rather many cases are misdiagnosed
or may not even be diagnosed at all, because of the
clinical evaluation alone is especially difficult and
often not definitive [4]. Thus, an evidence-based,
early, accurate, and fast diagnostic approach is in
great need. Fortunately, next-generation sequencing
(NGS) methods have been shown to be a powerful
tool for the diagnosis of genetic or presumed genetic
disorders [16, 17]. In this study, we accurately diag-
nosed two HS patients using NGS and presented their
comprehensive ophthalmic examinations. We further
reviewed the varied phenotypes and genotypes of all
previously reported cases, and uncovered novel geno-
type–phenotype correlations.
Methods
Subjects and ethics statement
The current study was performed in accordance with
the Code of Ethics of the World Medical Association
(Declaration of Helsinki) for medical research involving
human subjects, and was approved by the Ethics Com-
mittee of the Eye & ENT Hospital of Fudan University.
Two HS patients and their relatives were recruited after
obtaining informed consent.
Clinical evaluation and sample collection
Both patients underwent a full ophthalmic examination,
including best corrected Snellen visual acuity testing
(BCVA), color vision (Ishihara color plate), slit lamp bio-
microscopy, tonometry, dilated fundus examination,
ultrasound biomicroscopy (UBM), A/B-ultrasound (MD-
300 L; MEDA Co., Ltd., Tianjin, China), wide-field fun-
dus imaging (Optos PLC, Dunfermline, United King-
dom), spectral domain optical coherence tomography
(SD-OCT, Spectralis HRA +OCT, Heidelberg, Engineer-
ing Inc., Heidelberg, Germany), full-field electroretinog-
raphy (ERG, according to the standards of the
International Society for Clinical Electrophysiology of
Vision; available at www.iscev.org), multifocal ERG
(mfERG, LKC Utas E3000 LKC Technologies Inc., USA),
and visual field (Humphrey Visual Field Analyzer, Carl
Zeiss Inc., CA, USA). Family and medical history includ-
ing subjective degree of vision loss, age of onset and
other related clinical manifestations were recorded.
Blood samples of all the patients and their family mem-
bers were collected from the peripheral blood and stored
at 4°Cbefore further analysis.
Genetic analyses and confirmation of suspected
pathogenic variants
DNA samples were extracted from whole blood using the
FlexiGene DNA Kit (Qiagen, Venlo, The Netherlands) ac-
cording to the manufacturer’s protocol. All participants in
this study were subjected to analysis using this panel-
based NGS. The capture panel contains exon-capture and
untranslated regions (UTRs) of 762 genes that are in-
volved in common inherited eye diseases (BGI-Shenzhen,
Additional file 3: Table S1). Acquisition of probe se-
quences: obtain the exon sequence and its flank ±30 bp of
762 genes from hg38. Each reference sequence begins at
one end of a reference sequence and selects the reference
sequence of the predetermined length to obtain the probe
sequence so that the last total probe can cover the refer-
ence sequence at least once, and the probe length of the
panel is 90 nt, the total target area obtained is 2.3 M.
On average, the mean coverage depth was more than
400X and the coverage of target region was around
99.9% by using BGISEQ-500. Subsequent points for
sample quality control have also been added to the
probe design process. After sequencing, data analysis
was performed as reported previously [18, 19].
Previously reported variants were determined using
ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/), the
Human Gene Mutation Database (HGMD Professional
2018.4, http://www.hgmd.cf.ac.uk/ac/index.php), and
locus-specific databases. Variants were classified as
pathogenic and likely pathogenic according to the
American College of Medical Genetics (ACMG) and
genomics guidelines for the more recent cases. Before
confirmation by Sanger sequencing, the candidate var-
iants were reviewed by clinical geneticists and oph-
thalmologists. Segregation analysis was performed
within family members.
Results
Genetic analyses of the two patients
Two previously reported mutations, c.2966T>C (p.Ile989Thr,
maternally inherited) and c.2097_2098insT (p.Phe699Phefs*43,
paternally inherited) [2, 9], were found in patient 1. A
known missense mutation, c.2966 T > C (p.Ile989Thr,
maternally inherited) [2, 9], and a novel likely patho-
genic mutation, c.895_896insTATA (p.Asn299Ilefs*2,
paternally inherited), were found in patient 2. Pedi-
grees and identified mutations of the two families are
shown in Fig. 1. We found no additional pathogenic
or likely pathogenic variants known to be associated
with inherited eye diseases in either patient.
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Clinical features of the two patients
Patient 1 is a 9-year-old boy, and patient 2 is an 8-
year-old girl. Clinical characteristics of the two pa-
tients are summarized in Table 1. Their family history
was unremarkable. Both patients had SNHL since
birth and amelogenesis imperfecta on their secondary
teeth. Nails, development, and intelligence were nor-
mal (Additional file 1: Figure S1 and Additional file 2:
Figure S2). They suffered from a progressive decrease
in visual acuity and nyctalopia since birth. BCVA
values of patient 1 and 2 were 0.8/0.6 and 0.4/0.5, re-
spectively, and intraocular pressures were within the
normal range. There were no abnormalities in
anterior segments. Fundus examinations revealed mid-
peripheral and peripheral retinal pigmentation abnor-
malities in both patients, consistent with RP (Figs. 2
and 3). SD-OCT showed marked loss and disruption
of the ellipsoid zone, photoreceptor outer segment,
and retinal pigment epithelium (RPE). Cystoid macu-
lar edema (CME) was seen in both patients, although
cystoid spaces were larger and more frequent in pa-
tient 2. Interestingly, both patients were previously di-
agnosed with Usher syndrome as well as attention
deficit hyperactivity disorder (ADHD), their axial
lengths (20.69 mm/20.49 mm vs 20.17 mm/20.30 mm,
respectively) were shorter than their peers, and they
suffered from hyperopia (+ 3.25/+ 3.75 DS vs + 3.75/+
1.65 DS, respectively).
Follow-up visits were scheduled 2 months and 2 years
after the first visit of patient 2. At the 2-month visit,
CME was aggravated and the central foveal thickness
(CFT) increased from 510 to 603 μm in the right eye and
from 599 to 666 μm in the left eye; as a result, the BCVA
decreased from 0.6/0.7 to 0.4/0.5. At the third visit 2
years later, the CFT of both eyes had decreased spontan-
eously; however, through anatomic improvement, there
was no notable visual gain (Fig. 4). The thickness of all
other retinal layers showed no major change throughout
the 2 year-follow-up (Additional file 4: Table S2).
Genotype–phenotype correlations
Clinical and genetic characteristics of the previously re-
ported HS cases were analyzed and are listed in Table 2.
To date, 29 HS patients have been reported worldwide,
which gives a total of 31 including the two patients in
this study (male = 10, female = 21). Among the 29 re-
ported HS patients, most derive from the UK (n = 10)
and the USA (n = 8), while only one is of Chinese origin.
Twelve patients from seven families harbor PEX6 muta-
tions, 10 patients from eight families carry PEX1 muta-
tions, and two patients from two families have PEX26
mutations. No variants were identified in the currently
Fig. 1 Pedigrees (a) and identified mutations (a). a Circles represent females, and squares represent males. Filled symbols represent affected
patients, and empty symbols represent unaffected family members. b Sequencing results of the mutations in the PEX1 gene. Arrows indicate the
position of the mutated nucleotide
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Table 1 Summary of mutations, ophthalmologic findings, and other features of the two patients
Case 1 Case 2
Ethnicity/gender Chinese/male Chinese/female
Age of eye examination (years) 9 8
Mutation PEX1 c.2966 T > C; p.Ile989Thr
PEX1 c.2097_2098insT; p.Phe699Phefs*43
PEX1 c.895_896insTATA p.Asn299Ilefs*2 PEX1 c.2966 T >
C p.Ile989Thr
Family history Unremarkable Unremarkable
Ophthalmic findings
-IOP (mmhg) 10/10 9/10
-BCVA 0.8/0.6 0.4/0.5
- Cycloplegic refraction R: + 3.25/+ 2.75X85
L: + 3.75/+ 3.00X85
R: + 3.75/− 0.5X67
L: + 1.65/− 0.37X88
- Color amblyopia Color amblyopia N
- Cornea N N
-Corneal curvature R: 41.11/45.36 D
L: 41.01/44.53 D
R: 45.55/46.30 D
L: 45.98/46.49 D
-Central corneal thickness 563 um/563 um NA
- Anterior chamber depth 2. 65 mm/2.54 mm 1.99mm/1.99mm
- Iris N N
- Axial lengths 20.69 mm/20.49 mm 20.17mm/20.30 mm
- Lens N N
-UBM N N
- Retinal vessels N N
-Retina Retinal atrophy in the mid and far periphery
combined with significant bone spicule-like
pigmentation
Retinal atrophy in the mid and far periphery
combined with significant bone spicule-like
pigmentation
- Optic nerve The inferionasal rim of the optic disc is blurred
(R and L)
The inferionasal rim of the optic disc is blurred
(R and L)
-B scan Light to moderate turbidity in the front and
middle sections of the vitreous, posterior vitreous
detachment
Light turbidity in the front and middle sections
of the vitreous, posterior vitreous detachment
-RNFL thickness N N
-ffERG Profoundly attenuated rod ERGs, subnormal and
delayed cone ERGs.
Undetectable rod ERG, subnormal bright flash
ERG, subnormal and delayed cone ERG.
-mfERG Amplitudes in posterior-pole of both eyes were
significantly reduced, more seriously in the
right eye
Amplitudes in posterior-pole of both eyes were
significantly reduced, more seriously in the
right eye
-VEP Reduced of P100 amplitude. Prolongation of latency and lowness of amplitude.
- Humphrey visual field Peripheral visual field loss, with small central loss Peripheral visual field loss, except for the superior
nasal quadrant
- Goldman visual field NA Peripheral visual field constriction
-SD-OCT Centrally preserved ISe band with small retinal
cysts of the inner nuclear layer
Multiple large intraretinal cysts
- Orbital MRI N N
- Sensorineural hearing loss + +
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Table 1 Summary of mutations, ophthalmologic findings, and other features of the two patients (Continued)
Case 1 Case 2
-Teeth Amelogenesis imperfecta Amelogenesis imperfecta
- Nail abnormalities N N
- Intellect N N
- Electroencephalography The frequency of theta rhythm is slightly increased NA
- Development N N
- Psychomotor N N
Abbreviations. IOP intraocular pressure, BCVA best corrected visual acuity, R right, L left, SD-OCT spectral domain optical coherence tomography, UBM ultrasound
biomicroscopy, RNFL retinal nerve fiber layer, MRI magnetic resonance, ffERG full-field ERG, mfERG multifocal ERG, VEP visual evoked potential, ISe inner segment
ellipsoid, N normal, NA not assessed, + positive finding
Fig. 2 Ocular features of patient 1. a Ultra wide-field pseudocolor images showing retinal atrophy in the mid and far periphery combined with
significant bone spicule-like pigmentation and mottling in both eyes. b SD-OCT shows small macular cysts in the inner nuclear layer, a thickened
retina, and an atrophic photoreceptor layer with preservation of the ellipsoid zone (EZ) and the external limiting membrane (ELM). c Visual field
shows peripheral visual field loss, with small central loss. d mfERG shows that amplitudes in the posterior-pole of both eyes were significantly
reduced, more seriously in the right eye
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known PEX genes in four patients from two families by
exome sequencing [9], while genetic testing was under-
taken in three patients from three families. Together with
our study, 15 missense mutations (71.4%, PEX1 = 4/8,
PEX6 = 8/10, PEX26 = 3/3), four frameshift mutations
(19.0%, PEX1 = 2/8, PEX6 = 2/10), one nonsense mutation
Fig. 3 Ocular features of patient 2. a Ultra wide-field pseudocolor images showing retinal atrophy in the mid and far periphery combined with
significant bone spicule-like pigmentation, mottling in both eyes. b SD-OCT shows bilateral cystoid macular edema, which mainly involved the
outer nuclear layer (ONL). The foveal and peripheral macular ellipsoid zone (EZ) was disrupted and almost absent. c Visual field shows peripheral
visual field loss except for the superior nasal quadrant. d mfERG shows undetectable rod ERG, subnormal bright flash ERG, and subnormal and
delayed cone ERG
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(4.8%, PEX1 = 1/8), and one splicing mutation (4.8%,
PEX1 = 1/8) have been reported to be associated with HS.
Only 50 missense mutations (29.4%, PEX1 = 21/85,
PEX6 = 27/76, PEX26 = 2/9) were reported to be associ-
ated with Zellweger syndrome, which has a severe early-
lethal clinical presentation (Additional file 5: Table S3),
while the remaining 70.6% of variants are truncating stop
or frameshift defects.
The genotype of every HS patient include at least one
missense variant, except for two patients from one fam-
ily with a homozygous exon 23 nonsense variant,
c.3750G > A (p.Trp1250*). This variant is only 19 bases
from the last exon–exon boundary of PEX1, and it is
likely that the resultant transcript escapes nonsense-
mediated decay with little effect on protein function,
resulting in a mild phenotype. We found a genotype–
phenotype relationship in HS patients with retinal dys-
trophy that at least one mutation in PEX1 or PEX6 gene
affected the nucleotide sequence of the AAA-ATPase re-
gion in every patient, which is typically involved in bind-
ing of substrates or cofactors and is vital for the PEX
function19–21. These results suggesting that AAA-
ATPase region may is a hypermutable region in patients
with retinal dystrophy. The locations of these variants
are shown in Fig. 5.
All 31 patients were diagnosed with enamel defects of
the secondary teeth and SNHL. Twenty patients had RP
with or without macular cystoid dystrophy, while no
fundus examination was performed on the other four
patients so it is unknown if they had RP. Funduscopy of
five patients from two families was normal. Twelve pa-
tients have nail abnormalities, suggesting that this is not
an essential phenotype so should not be a clinical
diagnostic indicator for HS [12]. HS was shown to be a
rare disease with high phenotypic heterogeneity, with no
significant difference between PEX1-, PEX6-, and
PEX26-associated phenotypes.
Discussion
Phenotypic information about individual patients is often
insufficiently detailed or inaccessible, thus obstructing
the diagnosis of rare systemic diseases or those with
overlapping phenotypes. Gene panel sequencing achieves
high diagnostic rates in the context of a specific sus-
pected disease or group of diseases, and genetic results
can provide support for clinical diagnosis, modify future
disease risk, and inform the customization of a variety of
therapies [16, 17].
So far, our clinical knowledge and understanding of
HS are very limited and a diagnosis can easily be over-
looked or misdiagnosed. In this work, two patients previ-
ously diagnosed with Usher syndrome achieved an
accurate diagnosis of HS based on NGS. Additionally, a
novel pathogenic mutation and two unreported ocular
phenotypes were recognized, and four novel genotype–
phenotype correlations of HS were uncovered. This pro-
vides a deeper understanding of the clinical manifesta-
tions and pathogenesis of HS, which is vital for accurate
clinical practice, genetic counseling, and pathogenesis
studies.
No details of HS ophthalmic manifestations caused by
PEX1 mutations have been reported so far. In this work,
we present comprehensive ophthalmic examinations of
two HS patients induced by PEX1 mutations. As well as
the previously reported phenotypic features of RP with
CME, these patients also showed short axial lengths and
Fig. 4 Follow-up of central foveal thickness in patient 2
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hyperopia suggesting that PEX1 mutation-associated
ocular involvement can be developmental (short axial
length) and degenerative (RP). Both patients also had
ADHD which may be a novel phenotype of HS. After
comprehensively analyzing the varied phenotypes of all
reported HS cases in the literature, we propose that HS
is a systemic disorder with high phenotypic variability;
however, all cases demonstrate SNHL (severe to pro-
found) and enamel hypoplasia of secondary dentition.
Most patients show infantile-onset retinal dystrophy,
and nails are normal or abnormal. They may also suffer
from other systemic abnormalities such as learning dis-
abilities or ADHD. Considering the wide clinical hetero-
geneity, rapid and definitive diagnosis of HS is
challenging, and it is especially difficult to establish clin-
ical diagnostic criteria. NGS can help resolve these chal-
lenges, and we suggest that it should become the “gold
standard” for diagnosing HS.
Through a comprehensive analysis of the reported mu-
tant genes we found that mutations in PEX1 and PEX6 are
the main cause of HS. A small number of cases are also
caused by mutations in PEX26, and it is likely that other
HS-causing genes remain to be discovered. PEX1 and
PEX6 are members of the AAA protein family that are in-
volved in binding ATP to form a heterohexameric ATPase
which is associated with various cellular activities that fuel
essential protein transport across peroxisomal membranes
[20, 21]. They also play a key role in matrix protein import
from heterohexamers and ternary complexes with PEX26
[22]. Mutant PEX6 and PEX1 proteins result in abnormal
peroxisomal function, leading to the accumulation of very
long chain fatty acids in photoreceptors, RPE, and
pigment-laden macrophages [10, 23].
Genotype–phenotype analysis in this study revealed
that HS is caused by genotypes including at least one
missense variant, while Zellweger syndrome was
caused by more deleterious genotypes, such as trun-
cating stop or frameshift defects. Furthermore, at least
one mutation in one patient affects the AAA-ATPase
region (PEX1 and PEX6) or PEX6 binding site
(PEX26) when HS patients have retinal dystrophy. To-
gether, these results we speculate that hypomorphic
mutations in PEX result in a partially functional protein
[24, 25], mutations in AAA-ATPases play a role in retinal
dystrophy, and AAA-ATPase region is a hypermutable re-
gion in patients with a retinal dystrophy. No significant
difference was found among PEX1-, PEX6-, and PEX26-
associated phenotypes, perhaps because these genes
closely interact in vivo so any mutation in a given gene af-
fects the function of the entire complex [26, 27]. It is also
conceivable that a single genetic locus cannot explain the
full phenotypic spectrum, and we propose that additional
genetic and possibly nongenetic modifiers cause the vari-
ous phenotypes.
Fig. 5 Location of HS-associated variants in PEX1, PEX6 and PEX26. Black: missense mutation. Blue: splicing mutation. Red: frameshift mutation.
Green: nonsense mutation
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One limitation of this study is that the genotype–
phenotype correlations were based on only 31 HS pa-
tients. Therefore, these correlations should be confirmed
in more HS patients in future studies. Additionally, only
one HS patient was followed up over a 2-year period,
which may not accurately reflect the progress of the dis-
ease. Longer follow-up in more HS patients is required
to better understand the ocular prognosis of this disease.
Conclusions
To summarize, we report two HS families diagnosed by
NGS and present the first comprehensive report of the
HS ophthalmic phenotype. We identified a novel patho-
genic mutation and two unreported ocular phenotypes,
which expands the known mutation and clinical spectra
of HS. Furthermore, we propose that HS is a systemic
disorder with high phenotypic heterogeneity, and show
the importance of NGS in the diagnosis of HS. Three
novel genotype–phenotype correlations of HS were also
uncovered, which is useful for accurate clinical practice,
genetic counseling, and pathogenesis studies. These data
should be validated and expanded in additional studies.
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